{"product_id":"cstl-ansoff-analysis","title":"(CSTL) Castle Biosciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Castle Biosciences, Inc. Ansoff Matrix Analysis helps you quickly evaluate growth options across market penetration, market development, product development, and diversification in one concise framework; the page already includes a real preview\/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for strategy, investing, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-Melanoma in invasive cutaneous melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-Melanoma is Castle Biosciences, Inc.'s core assay for invasive cutaneous melanoma, where about 90% of melanoma cases arise. Market penetration comes from more repeat ordering inside the same dermatologist and oncology networks, not new buyer groups. That makes it a deepening play in the company’s main melanoma market, with each added order raising use per provider.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-UM in uveal melanoma specialty care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-UM targets a rare cancer with about 5 to 6 new uveal melanoma cases per 1 million people each year in the U.S., so penetration hinges on adoption by ocular oncologists and retina-linked care teams. The test helps forecast metastasis risk after diagnosis, and that fits an existing oncology workflow rather than creating a new one. Wider use can deepen Castle Biosciences, Inc.'s share of a niche specialty segment where clinical utility matters more than broad volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-SCC in high-risk cutaneous squamous cell carcinoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-SCC is a 40-gene expression profile used in patients with recognized high-risk cutaneous squamous cell carcinoma, and it is positioned for metastasis risk stratification, not diagnosis. That focus gives Castle Biosciences, Inc. a way to sell more tests within the same skin-cancer workflow.\u003c\/p\u003e\n\u003cp\u003eGreater use in dermatology and surgical oncology can raise share if clinicians adopt it for post-biopsy decision-making. The test’s value is clearest when standard pathology leaves uncertainty on who needs closer follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003emyPath Melanoma and DecisionDx DiffDx-Melanoma in ambiguous lesions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003emyPath Melanoma and DecisionDx DiffDx-Melanoma fit a recurring need in uncertain pigmented lesions, so Castle Biosciences can win more cases by becoming part of the standard workup. In 2024, Castle Biosciences reported $310.7 million in total revenue, showing a base to scale deeper adoption in existing markets. \u003c\/p\u003e\n\u003cp\u003eThese tests help separate hard-to-read melanocytic lesions, which supports repeat use in dermatology and pathology workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets ambiguous melanocytic lesions\u003c\/li\u003e\n\u003cli\u003eFits existing diagnostic workflows\u003c\/li\u003e\n\u003cli\u003eSupports deeper market adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProvider-ordered commercial model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences’ provider-ordered model fits market penetration because physicians order the tests inside existing care pathways, which supports repeat use without hunting new end buyers. That helps Castle deepen share in current dermatology and oncology networks, while clinical validation and payer coverage make adoption easier for the same customers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrders flow through healthcare providers.\u003c\/li\u003e\n\u003cli\u003eRepeat use comes from existing networks.\u003c\/li\u003e\n\u003cli\u003eValidation and payer access lift retention.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences grows by selling more tests into the same networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences, Inc. drives market penetration by selling more tests to the same dermatology and oncology networks, not by chasing new buyers. In 2024, revenue was $310.7 million, showing room to deepen use of DecisionDx, myPath, and DiffDx inside existing workflows. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$310.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore play\u003c\/td\u003e\n\u003ctd\u003eRepeat orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget users\u003c\/td\u003e\n\u003ctd\u003eDermatology, oncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Castle Biosciences, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, structured Ansoff Matrix for Castle Biosciences, Inc. to clarify growth options and reduce strategic planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists verified Castle Biosciences sources to fast-track Ansoff Matrix assumptions and trace each growth path to credible references.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcular oncology reach with DecisionDx-UM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-UM moves Castle Biosciences from cutaneous melanoma into ocular oncology, serving uveal melanoma specialists with the same metastasis-risk model. Uveal melanoma is rare, at about 5 to 6 cases per million people a year, so this is market development: one test, new physician group, new disease site. It also broadens Castle beyond skin cancer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-melanoma skin cancer reach with DecisionDx-SCC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-SCC moved Castle Biosciences beyond melanoma into high-risk cutaneous squamous cell carcinoma, a large non-melanoma skin cancer pool that sits inside the more than 1.8 million U.S. annual skin-cancer cases. That widens the addressable market from melanoma-focused users to dermatologists and surgical oncologists managing cSCC. It also gives Castle Biosciences a second skin-cancer growth lane, which can lift test volume and reduce reliance on one disease segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic workups for ambiguous pigmented lesions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx DiffDx-Melanoma and myPath Melanoma move Castle Biosciences into the diagnostic workup for ambiguous pigmented lesions, not just prognosis. That means the buying decision sits in the pathology workflow, where clinicians need lesion classification, not metastatic-risk scoring. With 2 melanoma-focused assays, Castle can target a broader point in care and expand use beyond one clinical question.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader physician specialties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences, Inc. uses the same test menu across 4 clinician groups: dermatologists, dermatopathologists, surgical oncologists, and ocular oncologists. That is a classic market-development move, because it adds new buyer groups without changing the core tests. It widens ordering access and can lift test volume from the same diagnostic assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 specialties, same menu\u003c\/li\u003e\n\u003cli\u003eMore ordering channels\u003c\/li\u003e\n\u003cli\u003eHigher volume potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple dermatology-related care settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences uses existing assays in multiple skin-cancer settings: melanoma, uveal melanoma, cSCC, and ambiguous lesions. That broad portfolio turns market development into a low-friction move into adjacent clinical uses, not a new product launch. It also helps the Company reach more dermatology and oncology decision points with one test platform.\u003c\/p\u003e\n\u003cp\u003eIn practice, the same commercial engine can serve more care settings as clinicians face different lesion types and risk questions. The key growth lever is extending current assays into these nearby use cases, so Castle Biosciences can add revenue without rebuilding its core diagnostic workflow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour key skin-cancer use cases\u003c\/li\u003e\n\u003cli\u003eExisting assays, adjacent demand\u003c\/li\u003e\n\u003cli\u003eMarket development, not new R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences Expands Into New Specialty Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences uses existing assays to enter adjacent specialties and diseases: uveal melanoma at 5 to 6 cases per million yearly, cSCC inside 1.8 million U.S. skin-cancer cases, and ambiguous pigmented lesions in pathology. That is market development: same test base, new buyer groups, wider clinical use, and higher volume potential.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUse case\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecisionDx-UM\u003c\/td\u003e\n\u003ctd\u003eOcular oncology\u003c\/td\u003e\n\u003ctd\u003e5 to 6 per million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecisionDx-SCC\u003c\/td\u003e\n\u003ctd\u003ecSCC\u003c\/td\u003e\n\u003ctd\u003e1.8 million U.S. skin cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiffDx-Melanoma, myPath\u003c\/td\u003e\n\u003ctd\u003ePathology\u003c\/td\u003e\n\u003ctd\u003eNew buying point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCastle Biosciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report, and once purchased you’ll get the complete, editable Ansoff Matrix for Castle Biosciences, Inc., ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-UM launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences, Inc. launched DecisionDx-UM to forecast metastasis risk in uveal melanoma, a rare cancer with about 5 to 6 U.S. cases per million people each year. The gene-expression profiling test filled a clear clinical gap and expanded Castle Biosciences, Inc.’s melanoma-focused menu into a distinct, higher-value niche. That product move supports Ansoff matrix product development: same market, new test, stronger differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-SCC launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-SCC is Castle Biosciences, Inc.'s 40-gene expression profile for cutaneous squamous cell carcinoma, adding a second skin-cancer risk test beyond melanoma. It supports product development by widening the menu into a separate, clinically distinct market. The launch fits a related-diversification move, and the 40-gene assay gives Castle a new tool for risk stratification in SCC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx DiffDx-Melanoma launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx DiffDx-Melanoma adds a diagnostic use case for ambiguous pigmented lesions, so Castle Biosciences, Inc. can serve the same dermatology workflow with both diagnosis and prognosis. That broadens its portfolio beyond prognostic tests and strengthens cross-sell inside one clinical channel. It also supports the same melanoma ecosystem where Castle reported $319.0 million in 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003emyPath Melanoma launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003emyPath Melanoma broadens Castle Biosciences, Inc.'s dermatology franchise by adding a second proprietary test for hard-to-read pigmented lesions, so existing dermatology and pathology users can stay in one workflow. It targets a different clinical question than the company’s prognosis assays, which should deepen use rather than overlap it. In the U.S., melanoma cases are expected to top 104,960 in 2025, which keeps demand for better lesion triage high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecond test for the same users\u003c\/li\u003e\n\u003cli\u003eNew diagnosis use, not prognosis\u003c\/li\u003e\n\u003cli\u003eFits a large 2025 melanoma market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-test proprietary portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences, Inc. has built a multi-test proprietary gene-expression profiling portfolio, so it is not tied to one assay. That supports Ansoff product development: the Company adds indication-specific tests on the same molecular-testing platform, which gives clinicians more choices in current markets and lets Castle sell into the same specialty channels with lower platform risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple tests, one platform\u003c\/li\u003e\n\u003cli\u003eMore options in current markets\u003c\/li\u003e\n\u003cli\u003eLess dependence on one assay\u003c\/li\u003e\n\u003cli\u003eClear product-development fit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences Expands Dermatology Reach with New Gene-Expression Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences, Inc. fits product development by adding new gene-expression tests to the same dermatology channels. DecisionDx-UM, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, and myPath Melanoma widen use without changing the core market. U.S. melanoma cases are expected to exceed 104,960 in 2025, and Castle Biosciences, Inc. reported 319.0 million dollars of 2024 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecisionDx-UM\u003c\/td\u003e\n\u003ctd\u003eUveal melanoma risk\u003c\/td\u003e\n\u003ctd\u003eSame market, new test\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emyPath Melanoma\u003c\/td\u003e\n\u003ctd\u003eLesion diagnosis\u003c\/td\u003e\n\u003ctd\u003eMore workflow depth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTissueCypher Barrett’s Esophagus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTissueCypher Barrett’s Esophagus moves Castle Biosciences beyond dermatologic cancer into a new disease area, so it is a clear new-product, new-market step in the Ansoff Matrix. This proteomic assay helps estimate Barrett’s progression risk and broadens Castle’s test menu beyond its core skin cancer diagnostics. The move matters because Barrett’s affects about 1% to 2% of adults in the U.S., giving Castle a large adjacent addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterology and endoscopic surveillance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences’ push into gastroenterology and endoscopic surveillance is diversification in the Ansoff Matrix: it sells a different product into a new clinical workflow. Barrett’s esophagus is managed in GI and endoscopy settings, so this move broadens Castle beyond dermatology and oncology customers. The U.S. Barrett’s burden is large, with an estimated 1% to 2% prevalence in adults.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProteomic testing platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTissueCypher is a proteomic platform, so Castle Biosciences, Inc. is diversifying beyond its core skin-cancer gene-expression-profile tests into a different technology and a broader GI market. That lowers dependence on one diagnostic category and one biology stack. In 2024, Castle Biosciences, Inc. reported about $236 million in total revenue, so adding non-skin tests can widen the base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePost-acquisition portfolio expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences widened beyond dermatology when it bought Cernostics and added TissueCypher, a machine-learning test for esophageal precancer risk. That was classic diversification through M\u0026amp;A: one acquisition added a new clinical use, a new patient group, and a broader portfolio rather than just more volume in the same market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdded a new clinical application\u003c\/li\u003e\n\u003cli\u003eExpanded beyond skin cancer tests\u003c\/li\u003e\n\u003cli\u003eBuilt portfolio value through M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBeyond cancer metastasis prediction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences is moving beyond melanoma, uveal melanoma, and cSCC by using TissueCypher to measure progression risk in Barrett's esophagus, a premalignant condition that affects about 1% to 2% of adults. That shifts the Company from a dermatology-led base into gastroenterology and broader cancer-risk stratification. It also widens its addressable market beyond metastasis prediction into earlier intervention and lesion management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands beyond skin cancer.\u003c\/li\u003e\n\u003cli\u003eTissueCypher targets esophageal progression risk.\u003c\/li\u003e\n\u003cli\u003eBarrett's esophagus broadens Castle's market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences Expands TissueCypher Into a New GI Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences, Inc. shows diversification in the Ansoff Matrix by moving TissueCypher into Barrett’s esophagus, a new disease area outside its core dermatology tests. That adds a new product, a new GI workflow, and a broader addressable market, since Barrett’s esophagus affects about 1% to 2% of U.S. adults.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissueCypher\u003c\/td\u003e\n\u003ctd\u003eNew product, new market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003eGI and endoscopy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234196070665,"sku":"cstl-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/cstl-ansoff-matrix.webp?v=1785715995","url":"https:\/\/dcfanalyst.com\/products\/cstl-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}